NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: Rossetti

APRIL 30, 2011 – 9:00 AM – 03:30 PM

CHAIR: F. SAAD

(03:30 PM – 04:30 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

– To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
– To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
– To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
– To provide a learning environment supportive to new investigators.
– To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

9:00 am  WELCOME AND APPROVAL OF PREVIOUS MINUTES

9:10 am  SPRING MEETING CME ACCREDITATION

9:20 am  NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN

PR.11
PR.13 (RADICALS)/MRC PR.10

L. Klotz
C. Catton/F. Saad

10:00 am  NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED. PENDING ANALYSES

PR.3
PR.8/SWOG 9346
BL 8/EORTC 30994
REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC

P. Warde/ M. Brundage
B. Donnelly
L. Wood
M. Jewett/ L. Wood

10:15 am  COFFEE BREAK

continued on next page …
10:30 am  **NCIC CTG Phase III Trials: Recent Analyses**

PR.7  J. Crook/ L. Klotz/ C. O’Callaghan

10:45 am  **CTSU Trials Activated by NCIC CTG: Open**

PRC.2/CALGB 90202  Early Versus Standard Zoledronic Acid in CaP metastatic to bone  F. Saad
PRC.3/CALGB 90203  Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only  M. Gleave/ W. Parulekar

11:00 am  **NCIC CTG IND Trials**

IND.195: A Phase II Study of SB 939 in Patients with CRPC  B. Eigl/ K. Chi

11:10 am  **Open CUOG Trials**

11:30 am  **New Trial Proposals**

Phase III Study of HDR Brachytherapy in Intermediate Risk CaP  E. Vigneault/ A. Loblaw

12:00 pm  **Lunch**

1:30 pm  **Update on Closed CUOG Trials**

2:00 pm  **Dog Reports**

Localized Prostate Cancer  A. Loblaw/ N. Fleshner
Advanced Prostate Cancer  K. Chi/ F. Saad
Advanced Bladder  W. Kassouf/ S. North
Renal  J. Knox/ A. Kapoor
Testes  C. Kollaansberger/ P. Chung
Superficial bladder  A. So

3:10 pm  **Open Discussion: New Business, Strategic Planning**

3:30 pm  **Meeting Adjourned, Executive Committee Meeting to Follow (Closed)**